Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer

European Urology

Volumn 65, Issue 4, 2014, Pages 816-824

  Keating, Nancy L ^a,b   Liu, Pang Hsiang ^b   O'Malley, A James ^b   Freedland, Stephen J ^c,d   Smith, Matthew R ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Androgen deprivation therapy; Diabetes; Prostate cancer

Indexed keywords

ANDROGEN-DEPRIVATION THERAPY; DIABETES; PROSTATE CANCER;

AGED; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84894449547     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.02.023     Document Type: Article

References (29)

1. M.R. Smith, J.S. Finkelstein, and F.J. McGovern et al. Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2002 599 603
2. M.R. Smith, H. Lee, and F. McGovern et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome Cancer 112 2008 2188 2194
3. M.R. Smith, H. Lee, and D.M. Nathan Insulin sensitivity during combined androgen blockade for prostate cancer J Clin Endocrinol Metab 91 2006 1305 1308
4. J.C. Smith, S. Bennett, and L.M. Evans et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer J Clin Endocrinol Metab 86 2001 4261 4267
5. F. Dockery, C.J. Bulpitt, S. Agarwal, M. Donaldson, and C. Rajkumar Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia Clin Sci (Lond) 104 2003 195 201
6. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
7. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
8. S.M. Alibhai, M. Duong-Hua, and R. Sutradhar et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes J Clin Oncol 27 2009 3452 3458
9. M.J. Lage, B.L. Barber, and R.A. Markus Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer Urology 70 2007 1104 1108
10. I.H. Derweesh, C.J. Diblasio, and M.C. Kincade et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer BJU Int 100 2007 1060 1065
11. A. Haidar, A. Yassin, F. Saad, and R. Shabsigh Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes Aging Male 10 2007 189 196
12. American Diabetes A Standards of medical care in diabetes Diabetes Care 28 Suppl 1 2005 S4 S36
13. D.B. Sacks, D.E. Bruns, D.E. Goldstein, N.K. Maclaren, J.M. McDonald, and M. Parrott Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus Clin Chem 48 2002 436 472
14. D. Rubin Multiple imputation for nonresponse in surveys 1987 Wiley New York, NY
15. C.N. Klabunde, A.L. Potosky, J.M. Legler, and J.L. Warren Development of a comorbidity index using physician claims data J Clin Epidemiol 53 2000 1258 1267
16. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64 2013 159 166
17. O. Ashenfelter, and D. Card Using the longitudinal structure of earnings to estimate the effects of training programs Rev Econ Stat 67 1985 648 660
18. M.R. Cooperberg, G.D. Grossfeld, D.P. Lubeck, and P.R. Carroll National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 2003 981 989
19. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, E. Orihuela, and J.S. Goodwin Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer 103 2005 1615 1624
20. B. Hemmingsen, L.L. Christensen, and J. Wetterslev et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses BMJ 344 2012 e1771
21. I.M. Stratton, A.I. Adler, and H.A. Neil et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412
22. G.N. Levine, A.V. D'Amico, P. Berger American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology Circulation 121 2010 833 840
23. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology, v.3.2012. Prostate cancer. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician-gls/PDF/prostate.pdf.
24. E.B. Lamont, M.B. Landrum, N.L. Keating, S.R. Bozeman, and B.J. McNeil Evaluating colorectal cancer care in the Veterans Health Administration: how good are the data? J Geriatric Oncol 2 2011 187 193
25. Healthcare Effectiveness Data and Information Set (HEDIS) 2004 technical specifications. Washington, DC; National Committee for Quality Assurance; 2004.
26. N.L. Keating, M.B. Landrum, B.E. Landon, J.Z. Ayanian, C. Borbas, and E. Guadagnoli Measuring the quality of diabetes care - comparison of administrative data and medical record data Health Serv Res 38 2003 1529 1545
27. N.L. Keating, M.B. Landrum, and B.E. Landon et al. The influence of physicians' practice management strategies and financial arrangements on quality of care among patients with diabetes Med Care 42 2004 829 839
28. G.S. Cooper, Z. Yuan, K.C. Stange, L.K. Dennis, S.B. Amini, and A.A. Rimm Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment Med Care 38 2000 411 421
29. G.S. Cooper, B. Virnig, C.N. Klabunde, N. Schussler, J. Freeman, and J.L. Warren Use of SEER-Medicare data for measuring cancer surgery Med Care 40 Suppl 8 2002 IV-43 48